

# In brief.

## Branded products in diabetes care commercialized by Sanofi under an exclusive worldwide license



Lixisenatide is marketed as Adlyxin® in the U.S. and is approved as Lyxumia® in more than 60 countries worldwide and marketed in over 40 of these by Sanofi. Commercial launches include most EU countries, Japan, Brazil, Mexico and India.



Soliqua™ 100/33 is a combination of lixisenatide and Lantus® and is marketed by Sanofi in the U.S. The product was approved as Suliqua™ in the EU in January 2017. Suliqua™ will be delivered in two pre-filled SoloSTAR® pens, providing different dosing options.

## Product pipeline



### 3 fully owned product candidates in Phase 2

- Glepaglutide\* for short bowel syndrome (SBS)
- Dasiglucagon\* for acute, severe hypoglycemia
- Dasiglucagon\* for type 1 diabetes care



### 3 product candidates in partnerships

- Elsiglutide for chemotherapy-induced diarrhea
- A dual GLP1-GLU for obesity/type 2 diabetes
- An undisclosed target for obesity/type 2 diabetes

## Scientific focus and platform



### Drug discovery

We invent and develop medicines focusing on specialty gastrointestinal and metabolic diseases.



### Peptides

Zealand has a successful 18-year history of discovering and optimizing peptide therapeutics as novel drugs.

\* Glepaglutide and dasiglucagon are proposed International Nonproprietary Names (pINN).

## Our approach


We build for success by maintaining a lean and agile organization and by partnering with the best in their fields, leading to greater efficiency and better results.

We have a history of successful outlicensing partnerships. Going forward, we will engage in partnerships across all stages of the value chain, but we will retain greater control and profitability.


In 2016, we partnered with high-quality device and drug manufacturers and leading centers and hospitals to run our clinical development.

## Financials


### 2016 year-end cash position



### 2012-2016 revenue



### 2016 revenue




## Employees are one of our biggest assets

### We aspire

to attract, develop and retain the best people and to be a company where employees thrive, regardless of their background.

### 122 employees

More than 80% of our employees work in R&D, and 36 of our employees hold a PhD.



## How we work

We have strengthened our organization with competencies enabling us to advance our product candidates through to registration and we will continue to expand our organization with relevant skills to fulfill our ambition, while maintaining our agility and leanness.

## Zealand Pharma A/S

### Based in Denmark

– home to a world-leading healthcare industry.

– and the country with the largest commercial drug development pipeline in Europe, according to investindk.com.

### Founded in 1998

to design and develop peptide-based medicines.

### Listed

on Nasdaq Copenhagen: ZEAL